The price of Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) shares last traded on Wall Street fell -1.94% to $15.69.
TEVA stock price is now -19.02% away from the 50-day moving average and -12.20% away from the 200-day moving average. The market capitalization of the company currently stands at $17.98B.
With the price target maintained at $20, Argus recently Upgraded its rating from Hold to Buy for Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA). On March 08, 2024, JP Morgan Upgraded its previous ‘Underweight’ rating to ‘Neutral’ on the stock keeping its target price maintained at $14, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Fox Christine, Officer bought 6,181 shares of the company’s stock on Mar 04 ’25. The stock was bought for $98,896 at an average price of $16.00. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 04 ’25, Officer McAvoy David R. bought 4,827 shares of the business’s stock. A total of $77,232 was incurred on buying the stock at an average price of $16.00. A total of 0.02% of the company’s stock is owned by insiders.
During the past 12 months, Teva- Pharmaceutical Industries Ltd. ADR has had a low of $12.51 and a high of $22.80. As of last week, the company has a debt-to-equity ratio of 3.38, a current ratio of 0.98, and a quick ratio of 0.75.
The net profit margin was -9.91% and return on equity was -25.44% for TEVA. The company reported revenue of $4.23 billion for the quarter, compared to $4.46 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.12 percent.
